Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenstr öm Macroglobulinemia
AbstractPurpose of ReviewThe treatment of Waldenstr öm macroglobulinemia (WM) has evolved over the past decade. With the seminal discoveries ofMYD88 andCXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) mutations in WM cells, our understanding of the disease biology and treatment has improved. The development of a new class of agents, Bruton tyrosine kinase inhibitors (BTKi), has substantially impacted the treatment paradigm of WM. Herein, we review the current and emerging BTKi and the evidence for their use in WM.Recent FindingsClinical trials have established the role of covalent BTKi in the treatm...
Source: Current Hematologic Malignancy Reports - March 27, 2024 Category: Hematology Source Type: research
ANCA-associated vasculitis presenting with isolated neurological manifestations in a patient with cocaine abuse: a case report and literature review
We present a unique case of AAV with isolated neurological manifestations presenting with multiple cranial neuropathies, leptomeningeal enhancement on imaging and histopathologic evidence of small-vessel vasculitis in the leptomeninges and brain and extensive dural fibrosis in a patient with cocaine abuse. The patient ’s progressive neurological deficits were controlled after starting immunosuppression with rituximab and prednisone. We also reviewed the literature to provide the diagnostic overview of AAV and evaluate intervention options. To our knowledge, this is the first case of AAV with isolated neurologic al manife...
Source: Clinical Rheumatology - March 26, 2024 Category: Rheumatology Source Type: research
Cancers, Vol. 16, Pages 1285: Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study
In conclusion, R-B followed by rituximab maintenance therapy in patients with previously untreated FL resulted in significantly longer PFS than R-CHOP, with older patients also benefiting from this treatment without further toxicity. Adverse events during maintenance were more frequent with R-B without impacting mortality. (Source: Cancers)
Source: Cancers - March 26, 2024 Category: Cancer & Oncology Authors: Mariana Bastos-Oreiro Antonio Gutierrez Almudena Cabero Javier L ópez Paola Villafuerte Ana Jim énez-Ubieto Raquel de O ña Adolfo De la Fuente Bel én Navarro Javier Pe ñalver Pilar Mart ínez Carmen Alonso Mar ía Infante Ra úl Córdoba Blanca Perez Tags: Article Source Type: research
Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
Primary membranous nephropathy (PMN) is the most common cause for adult nephrotic syndrome. Rituximab has demonstrated promising clinical efficacy by random controlled trials and the off-label use is widely adopted in PMN. However, the standard dosage is borrowed from B cell lymphoma treatment with far more antigens and is oversaturated for PMN treatment, accompanied with additional safety risk and unnecessary medical cost. More than 15% serious adverse events were observed under standard dosage and low dose therapies were explored recently. Dose optimization by clinical trials is extremely time- and cost-consuming and can...
Source: Frontiers in Pharmacology - March 26, 2024 Category: Drugs & Pharmacology Source Type: research
Cancers, Vol. 16, Pages 1288: Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts
Märklin
B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) therapy. On the other hand, monoclonal antibody therapy is increasingly used in both clinical trials and real-world settings. The introduction of rituximab has improved the outcomes in CD20 positive cases. Other monoclonal antibodies, such as tafasitamab (anti-CD19), obinutuzumab (...
Source: Cancers - March 26, 2024 Category: Cancer & Oncology Authors: Samuel J. Holzmayer Joseph Kauer Jonas Mauermann Tobias Roider Melanie M ärklin Tags: Article Source Type: research
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany
CONCLUSION: While most individuals started their treatment according to the treat-to-target approach and remained on their initially prescribed medication category, there has been a steadily increasing shift towards the EHT approach since 2020. These insights demonstrate that, while not officially recommended by German guidelines, MS providers increasingly adopt the EHT approach.PMID:38525488 | PMC:PMC10960977 | DOI:10.1177/17562864241237857 (Source: Adv Data)
Source: Adv Data - March 25, 2024 Category: Epidemiology Authors: Steffeni Papukchieva Ann-Sophie Stratil Maria Kahn Nils-Henning Ne ß Maike Hollnagel-Schmitz Vivien Gerencser Julia Rustemeier Markus Eberl Benjamin Friedrich Tjalf Ziemssen Source Type: research
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany
CONCLUSION: While most individuals started their treatment according to the treat-to-target approach and remained on their initially prescribed medication category, there has been a steadily increasing shift towards the EHT approach since 2020. These insights demonstrate that, while not officially recommended by German guidelines, MS providers increasingly adopt the EHT approach.PMID:38525488 | PMC:PMC10960977 | DOI:10.1177/17562864241237857 (Source: Adv Data)
Source: Adv Data - March 25, 2024 Category: Epidemiology Authors: Steffeni Papukchieva Ann-Sophie Stratil Maria Kahn Nils-Henning Ne ß Maike Hollnagel-Schmitz Vivien Gerencser Julia Rustemeier Markus Eberl Benjamin Friedrich Tjalf Ziemssen Source Type: research
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial
This study aimed to evaluate the usefulness of end-of-treatment (EOT)-PET for predicting PFS in FL patients in first relapse. EOT-PET examinations were performed between 6 and 8 weeks from the start of the last BR cycle. The primary endpoint was 1-year PFS. Key secondary endpoints were overall response rate (ORR), complete response rate (CRR), and 1-year overall survival (OS). Seventy-five patients were enrolled, and 8 were excluded from analysis. ORR was 86.6% and CRR was 59.7%. One-year PFS was 88.9% (95% confidence interval [CI] 80.7-94.3%) and 1-year OS in 75 patients was 97.3% (95% CI 89.6-99.3%). One-year PFS was sig...
Source: International Journal of Hematology - March 23, 2024 Category: Hematology Authors: Koji Kato Koji Izutsu Momoko Nishikori Hirohiko Shibayama Yoshinobu Maeda Kenichi Yoshimura Ukihide Tateishi Toshihiro Miyamoto Yasufumi Matsuda Jun Ishikawa Shinya Rai Tsutomu Takahashi Takahiro Yamauchi Itaru Matsumura Koichi Akashi Yuzuru Kanakura Junj Source Type: research
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
AbstractAs of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic. Most studies evaluated infliximab, while a smaller number evaluated adalimumab, rituximab or etanercept. Indications studied now include sarcoidosis, as well as the indications previously reported of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis and inflammatory bowel disease (Crohn ’s disease and ulcerative colitis). This updated data set includes eight additional studi...
Source: BioDrugs - March 23, 2024 Category: Drugs & Pharmacology Source Type: research
Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking
CONCLUSION: This study revealed biomarkers and Coptis chinensis-associated molecular functions for rituximab-resistant DLBCL.PMID:38517810 | DOI:10.3233/THC-230738 (Source: Technology and Health Care)
Source: Technology and Health Care - March 22, 2024 Category: Medical Devices Authors: Qiuling Zhao Shengqiang Huang Lin Yang Ting Chen Xiuliang Qiu Ruyi Huang Liangliang Dong Wenbin Liu Source Type: research
Autoimmune encephalitis in Israeli children - A retrospective nationwide study
Eur J Paediatr Neurol. 2024 Mar 15;50:1-5. doi: 10.1016/j.ejpn.2024.03.001. Online ahead of print.ABSTRACTImmune-mediated or autoimmune encephalitis (AE) is a relatively new, rare and elusive form of encephalitis in children. We retrospectively collected seropositive children (0-18 years old) with well characterized antibodies through 3 reference laboratories in Israel. Clinical symptoms, MRI and EEG findings and treatment courses were described. A total of 16 patients were included in the study, with 10 females. Anti NMDA encephalitis was most common followed by anti HU and anti mGLuR1. Psychiatric symptoms, abnormal move...
Source: European Journal of Paediatric Neurology - March 22, 2024 Category: Neurology Authors: Nimrod Sachs Efrat Zohar-Dayan Bruria Ben Zeev Tal Gilboa Mohammad Kurd Itay Tokatly Latzer Hadas Meirson Irit Krause Yotam Dizitzer Esther Ganelin Cohen Source Type: research
Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking
CONCLUSION: This study revealed biomarkers and Coptis chinensis-associated molecular functions for rituximab-resistant DLBCL.PMID:38517810 | DOI:10.3233/THC-230738 (Source: Technology and Health Care)
Source: Technology and Health Care - March 22, 2024 Category: Medical Devices Authors: Qiuling Zhao Shengqiang Huang Lin Yang Ting Chen Xiuliang Qiu Ruyi Huang Liangliang Dong Wenbin Liu Source Type: research
Autoimmune encephalitis in Israeli children - A retrospective nationwide study
Eur J Paediatr Neurol. 2024 Mar 15;50:1-5. doi: 10.1016/j.ejpn.2024.03.001. Online ahead of print.ABSTRACTImmune-mediated or autoimmune encephalitis (AE) is a relatively new, rare and elusive form of encephalitis in children. We retrospectively collected seropositive children (0-18 years old) with well characterized antibodies through 3 reference laboratories in Israel. Clinical symptoms, MRI and EEG findings and treatment courses were described. A total of 16 patients were included in the study, with 10 females. Anti NMDA encephalitis was most common followed by anti HU and anti mGLuR1. Psychiatric symptoms, abnormal move...
Source: European Journal of Paediatric Neurology - March 22, 2024 Category: Neurology Authors: Nimrod Sachs Efrat Zohar-Dayan Bruria Ben Zeev Tal Gilboa Mohammad Kurd Itay Tokatly Latzer Hadas Meirson Irit Krause Yotam Dizitzer Esther Ganelin Cohen Source Type: research
